Medicine and Dentistry
Patient
100%
Therapeutic Procedure
72%
Rituximab
33%
B-Cell Chronic Lymphocytic Leukemia
29%
Progression Free Survival
26%
Primary Central Nervous System Lymphoma
22%
Overall Survival
21%
Age
19%
Elderly Patient
16%
Toxicity
16%
Survival
16%
Non-Hodgkin Lymphoma
15%
Diagnosis
14%
Health Care Cost
13%
Combination Therapy
12%
Inpatient
12%
Assessment
11%
Hematology
10%
Follow up
10%
Second Cancer
10%
Standardized Incidence Ratio
10%
Mini-Mental State Examination Score
10%
White Matter
10%
Eosinophilia
10%
Fludarabine
10%
Polymerase Chain Reaction
10%
Invasive Aspergillosis
10%
Aspergillus
10%
Pyrrole
10%
Relative Survival
10%
Ixazomib
9%
Adult
9%
Dasatinib
8%
Association
8%
Granulocyte Colony Stimulating Factor
8%
Analysis
7%
Diseases
7%
Intravenous Drug Administration
7%
Evaluation Study
6%
Arm
6%
Dexamethasone
6%
Waldenström's Macroglobulinemia
6%
Magnetic Resonance Imaging
6%
Whole Brain Radiotherapy
6%
Acute Myeloid Leukemia
6%
Chronic Lymphocytic Leukemia
6%
Chemotherapy
6%
Burkitt's Lymphoma
6%
Brain
6%
Autologous Hematopoietic Stem Cell Transplantation
6%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
23%
Chronic Lymphatic Leukemia
19%
Chemotherapy
14%
Toxicity
13%
Standardized Incidence Ratio
10%
Second Cancer
10%
Fludarabine
10%
Aspergillus
10%
Invasive Aspergillosis
10%
Pyrrole
10%
Dasatinib
8%
Granulocyte Colony Stimulating Factor
8%
Primary Central Nervous System Lymphoma
7%
Progression Free Survival
7%
Nonhodgkin Lymphoma
7%
Waldenstroem macroglobulinemia
6%
Dexamethasone
6%
Antiapoptotic
6%
Overall Survival
6%